Home | Welcome to Contract Pharma   
Last Updated Sunday, April 20 2014
Print

Transgenomic, Amgen in Cancer Detection Pact



Published May 6, 2013
Related Searches: Development
Transgenomic, Inc. has entered into a collaboration with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations (KRAS and NRAS). These RAS mutations are identified with CE-IVD CRC RAScan kits using Surveyor-Wave technology, and provide physicians with important information regarding tumor mutation status. Financial terms were not disclosed.
 
“This collaboration with Amgen is indicative of how Transgenomic’s proprietary molecular technologies are advancing personalized medicine,” said Craig Tuttle, chief executive officer of Transgenomic. “This highly precise, innovative test was developed at Transgenomic’s laboratories, which excel in genomic and genetic analysis, novel technology development, and its application in clinical research and trials.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On